Data gathered: November 27
Alternative Data for Regenxbio
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 8 | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 11,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | 19 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,178 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,221 | Sign up | Sign up | Sign up |
| Twitter Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 59 | Sign up | Sign up | Sign up |
| Linkedin Employees | 363 | Sign up | Sign up | Sign up |
About Regenxbio
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
| Price | $10.01 |
| Target Price | Sign up |
| Volume | 467,420 |
| Market Cap | $475M |
| Year Range | $8.59 - $22.5 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Quest Partners LLC Lowers Holdings in REGENXBIO Inc. (NASDAQ:RGNX)November 27 - ETF Daily News |
 |
Chardan Capital Reiterates Buy Rating for REGENXBIO (NASDAQ:RGNX)November 23 - ETF Daily News |
 |
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapyNovember 19 - Yahoo |
 |
FDA endorses speedy approval path for Regenxbio Duchenne gene therapyNovember 17 - Yahoo |
 |
Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter ReportNovember 8 - Yahoo |
|
Harbor Capital Advisors Inc. Purchases 11,784 Shares of REGENXBIO Inc. (NASDAQ:RGNX)November 8 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 24M | 32M | -7.6M | -60M | -58M | -1.170 |
| Q2 '24 | 22M | 29M | -7.1M | -53M | -52M | -1.050 |
| Q1 '24 | 14M | 29M | -15M | -63M | -60M | -1.330 |
| Q4 '23 | 23M | 38M | -15M | -63M | -60M | -1.430 |
| Q3 '23 | 27M | 35M | -8.2M | -62M | -61M | -1.410 |
Insider Transactions View All
| KARABELAS ARGERIS N filed to sell 11,286 shares at $10.1. October 2 '24 |
| KARABELAS ARGERIS N filed to sell 11,286 shares at $12.3. September 4 '24 |
| KARABELAS ARGERIS N filed to sell 11,986 shares at $11.5. September 4 '24 |
| Simpson Curran filed to sell 170,037 shares at $15. August 5 '24 |
| KARABELAS ARGERIS N filed to sell 11,286 shares at $15. August 5 '24 |
Similar companies
Read more about Regenxbio (RGNX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Regenxbio?
The Market Cap of Regenxbio is $475M.
What is the current stock price of Regenxbio?
Currently, the price of one share of Regenxbio stock is $10.01.
How can I analyze the RGNX stock price chart for investment decisions?
The RGNX stock price chart above provides a comprehensive visual representation of Regenxbio's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Regenxbio shares. Our platform offers an up-to-date RGNX stock price chart, along with technical data analysis and alternative data insights.
Does RGNX offer dividends to its shareholders?
As of our latest update, Regenxbio (RGNX) does not offer dividends to its shareholders. Investors interested in Regenxbio should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Regenxbio?
Some of the similar stocks of Regenxbio are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.